Fragment‐Based Screen against HIV Protease

We have employed a fragment‐based screen against wild‐type (NL4‐3) HIV protease (PR) using the Active Sight fragment library and X‐ray crystallography. The experiments reveal two new binding sites for small molecules. PR was co‐crystallized with fragments, or crystals were soaked in fragment solutions, using five crystal forms, and 378 data sets were collected to 2.3–1.3 Å resolution. Fragment binding induces a distinct conformation and specific crystal form of TL‐3 inhibited PR during co‐crystallization. One fragment, 2‐methylcyclohexanol, binds in the ‘exo site’ adjacent to the Gly 16 Gly 17 Gln 18 loop where the amide of Gly 17 is a specific hydrogen bond donor, and hydrophobic contacts occur with the side chains of Lys 14 and Leu 63 . Another fragment, indole‐6‐carboxylic acid, binds on the ‘outside/top of the flap’ via hydrophobic contacts with Trp 42 , Pro 44 , Met 46 , and Lys 55 , a hydrogen bond with Val 56 , and a salt‐bridge with Arg 57 . 2‐acetyl‐benzothiophene also binds at this site. This study is the first fragment‐based crystallographic screen against HIV PR, and the first time that fragments were screened against an inhibitor‐bound drug target to search for compounds that both bind to novel sites and stabilize the inhibited conformation of the target.

[1]  Peter Kuhn,et al.  Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines. , 2002, Journal of synchrotron radiation.

[2]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[3]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[4]  Ana Gonzalez,et al.  Web-Ice: Integrated Data Collection and Analysis for Macromolecular Crystallography , 2008 .

[5]  Irene T Weber,et al.  Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. , 2006, Journal of molecular biology.

[6]  Turkan Haliloglu,et al.  Cooperative fluctuations of unliganded and substrate‐bound HIV‐1 protease: A structure‐based analysis on a variety of conformations from crystallography and molecular dynamics simulations , 2003, Proteins.

[7]  A. Gronenborn,et al.  A solution NMR study of the binding kinetics and the internal dynamics of an HIV‐1 protease‐substrate complex , 2003, Protein science : a publication of the Protein Society.

[8]  Wendy A. Warr,et al.  Fragment-based drug discovery , 2009, J. Comput. Aided Mol. Des..

[9]  J. Pflugrath,et al.  The finer things in X-ray diffraction data collection. , 1999, Acta crystallographica. Section D, Biological crystallography.

[10]  Irene T Weber,et al.  Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. , 2008, Accounts of chemical research.

[11]  Rieko Ishima,et al.  Rapid structural fluctuations of the free HIV protease flaps in solution: Relationship to crystal structures and comparison with predictions of dynamics calculations , 2002, Protein science : a publication of the Protein Society.

[12]  J. Andrew McCammon,et al.  A coarse grained model for the dynamics of flap opening in HIV-1 protease , 2005 .

[13]  T. Merigan,et al.  "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target. , 2005, Structure.

[14]  C. Simmerling,et al.  Solution structure of HIV-1 protease flaps probed by comparison of molecular dynamics simulation ensembles and EPR experiments. , 2008, Journal of the American Chemical Society.

[15]  J. Barreto,et al.  Antiretroviral Drugs , 2007, Journal of clinical pharmacology.

[16]  György M Keseru,et al.  Hit discovery and hit-to-lead approaches. , 2006, Drug discovery today.

[17]  P. Colman New antivirals and drug resistance. , 2009, Annual review of biochemistry.

[18]  H. Jhoti,et al.  A new school for screening , 2005, Nature Biotechnology.

[19]  Timothy McPhillips,et al.  New paradigm for macromolecular crystallography experiments at SSRL: automated crystal screening and remote data collection , 2008, Acta crystallographica. Section D, Biological crystallography.

[20]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[21]  Jung-Hsin Lin,et al.  Restrained molecular dynamics simulations of HIV‐1 protease: The first step in validating a new target for drug design , 2006, Biopolymers.

[22]  R. Alonso,et al.  Cytostatic and Cytotoxic Activity of Synthetic Diterpene Derivatives Obtained from (-)-Kaur-9(11), 16-Dien-19-Oic Acid Against Human Cancer Cell Lines , 2005 .

[23]  R. Poljak,et al.  The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. , 1991, Biochimie.

[24]  D. Goodsell,et al.  Identifying Protein Binding Sites and Optimal Ligands , 2005 .

[25]  S. Senapati,et al.  Molecular dynamics simulations of ligand-induced flap closing in HIV-1 protease approach X-ray resolution: establishing the role of bound water in the flap closing mechanism. , 2008, Biochemistry.

[26]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[27]  W. Scott,et al.  Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. , 2000, Structure.

[28]  D. Goodsell,et al.  Automated prediction of ligand‐binding sites in proteins , 2007, Proteins.

[29]  Mark Israel,et al.  XtalView, protein structure solution and protein graphics, a short history. , 2008, Journal of structural biology.

[30]  A G Leslie,et al.  Biological Crystallography Integration of Macromolecular Diffraction Data , 2022 .

[31]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[32]  D. Fattori,et al.  Fragment-based drug design: combining philosophy with technology. , 2007, Current opinion in drug discovery & development.

[33]  S. Kent,et al.  Dynamics of "flap" structures in three HIV-1 protease/inhibitor complexes probed by total chemical synthesis and pulse-EPR spectroscopy. , 2009, Journal of the American Chemical Society.

[34]  A. Leslie,et al.  The integration of macromolecular diffraction data. , 2006, Acta crystallographica. Section D, Biological crystallography.

[35]  J. Barreto,et al.  Antiretroviral drugs , 2007, Reactions Weekly.

[36]  Ladislau C. Kovari,et al.  Crystal Structures of a Multidrug-Resistant Human Immunodeficiency Virus Type 1 Protease Reveal an Expanded Active-Site Cavity , 2004, Journal of Virology.

[37]  Aina E Cohen,et al.  An automated system to mount cryo-cooled protein crystals on a synchrotron beam line, using compact sample cassettes and a small-scale robot. , 2002, Journal of applied crystallography.

[38]  J. Mccammon,et al.  HIV‐1 protease molecular dynamics of a wild‐type and of the V82F/I84V mutant: Possible contributions to drug resistance and a potential new target site for drugs , 2004, Protein science : a publication of the Protein Society.

[39]  Arthur J. Olson,et al.  Viral Evolution in Response to the Broad-Based Retroviral Protease Inhibitor TL-3 , 2001, Journal of Virology.

[40]  William A. Lee,et al.  Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring. , 2006, Journal of molecular biology.

[41]  G. Klebe,et al.  Targeting the Open‐Flap Conformation of HIV‐1 Protease with Pyrrolidine‐Based Inhibitors , 2008, ChemMedChem.

[42]  V. Hornak,et al.  Targeting structural flexibility in HIV-1 protease inhibitor binding. , 2007, Drug discovery today.

[43]  Robert M Stroud,et al.  Anisotropic dynamics of the JE-2147-HIV protease complex: drug resistance and thermodynamic binding mode examined in a 1.09 A structure. , 2002, Biochemistry.

[44]  E. Freire,et al.  Adaptive inhibitors of the HIV-1 protease. , 2005, Progress in biophysics and molecular biology.

[45]  G. Morris,et al.  Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3. , 2006, Journal of molecular biology.

[46]  C. Rouzioux,et al.  HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time , 2006, AIDS.

[47]  B. Torbett,et al.  Conformational flexibility in the flap domains of ligand-free HIV protease. , 2007, Acta crystallographica. Section D, Biological crystallography.

[48]  G. Fanucci,et al.  Interflap distances in HIV-1 protease determined by pulsed EPR measurements. , 2007, Journal of the American Chemical Society.

[49]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[50]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[51]  C. Craik,et al.  Trapping Moving Targets with Small Molecules , 2009, Science.

[52]  C. Simmerling,et al.  Drug pressure selected mutations in HIV-1 protease alter flap conformations. , 2009, Journal of the American Chemical Society.

[53]  Michael K Gilson,et al.  Evaluation of the substrate envelope hypothesis for inhibitors of HIV‐1 protease , 2007, Proteins.

[54]  M. Wainberg,et al.  Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection , 2004, AIDS.

[55]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[56]  I. Luque,et al.  Molecular basis of resistance to HIV-1 protease inhibition: a plausible hypothesis. , 1998, Biochemistry.

[57]  M F Sanner,et al.  Python: a programming language for software integration and development. , 1999, Journal of molecular graphics & modelling.

[58]  Alexander Hillisch,et al.  Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. , 2006, Drug discovery today.